Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Three confirmed partial responses observed in Phase 2a ACCENT trial
JustStocks Feature Article and Video Interview with Amplia CEO Dr Chris Burns
Recruitment of first 26 patients of Phase 2A ACCENT Trial now complete
Biotech Daily | Dr Boreham's Crucible: Amplia Therapeutics
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
Categories
Archive
Company News
Investor Newsletters
Videos
31 Jul 2023
Quarterly Activities and Cash Flow Report - 30 June 2023
Read More
20 Jul 2023
Investor Newsletter July 2023
Read More
19 Jul 2023
Dr Chris Burns to speak at Bio Connections Australia
Read More
1